From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area.
- Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care.
- Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care.
- Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon.
- Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
Introduction 1. When to Refer a Patient for CAR-T Cell Therapy 2. Optimizing the Apheresis Product 3. CAR T Cells: Cell Processing Laboratory Considerations 4. Peri-CAR-T Cell Management 5. Management of Cytokine Release Syndrome 6. Special Considerations for ICU Management of Patients Receiving CAR Therapy 7. Neurotoxicities After CAR-T Cell Immunotherapy 8. Hematologic and Non-CRS Toxicities 9. Response Assessment and PosteCAR-T Cell Therapy Management 10. Relapse Management and Role for Consolidative Hematopoietic Stem Cell Transplantation Following CAR-T Cell Therapy 11. Promising Chimeric Antigen Receptors for Non-B Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas 12. CAR T Cell Therapy for CNS Malignancies 13. CAR 2.0: The Next Generation of Synthetic ReceptoreBased Cellular Therapy for Cancer
